

GlaxoSmithKline (UK Ltd) and Hampshire and Isle of Wight Integrated Care System (NHS Hampshire, Southampton and Isle of Wight Clinical Commissioning Group) Executive Summary

Recharge COPD – Re evaluate COPD patients, Review therapy in line with local guidelines, Reduce carbon footprint

This summary has been written by GSK with consultation and approval from the Joint Working Project Team.

Hampshire and Isle of Wight Integrated Care System (NHS Hampshire, Southampton and Isle of Wight Clinical Commissioning Group) and GSK are undertaking a Joint Working project. The aims are to:

- Optimise therapy and align to local COPD guidelines ‘Hampshire COPD guideline’ in order to reduce exacerbations and breathlessness (where clinically appropriate and within licence)
- Align prescribing to ‘Investment and Impact Fund ‘Help create a more sustainable NHS’ enhanced service, where clinically appropriate for patients
- Increase engagement with the local respiratory network

This involves a balance of contributions from both parties with the pooling of skills, experience and resources. The project will run from April 2022 – December 2022. GSK will fund patient reviews via Interface Clinical Services (ICS) Ltd in up to 120 practices at an approximate cost of £7,059 per practice, to a total of approximately £847,085. In addition, GSK will contribute a total of approximately £17,200 in indirect costs such as colleagues’ time across the project. GSK will not have any influence over treatment decisions. GSK will not have access to patient medical records or personal information.

The NHS will contribute up to approximately 11,337 hours of resource across primary care colleagues’ time and GP Federation project management time at an approximate indirect cost of £5,945 per practice in up to 120 practices, to a total of approximately £713,394. The NHS contribution to the project does not include any transfer of money, it is based on the approximate costs of resource allocation.

Intended Benefits:

Patients	<ul style="list-style-type: none"> • Full review in line with local guidelines based on current therapy and risk stratification (patients may have not received a review otherwise or will receive quicker than when reviewed in yearly cycle) potentially increasing volume of those receiving a review, potentially leading to better outcomes • Optimisation of both non-pharmacological & pharmacological management • Potentially fewer COPD- related interventions, including hospital admissions • Better informed about COPD management and treatment options • COPD managed in accordance with current best practice clinical guidance • Better experience of the healthcare system – access to an Interface Clinical Service Clinical pharmacist and/or upskilled primary care clinician at their own GP practice
NHS	<ul style="list-style-type: none"> • Realisation of value-based healthcare objectives of improved patient outcomes with reduced Costs. • Support with risk stratification • Additional resource support, reviewing specific cohorts of patients • Guideline implementation resulting in consistent prescribing and non-prescribing recommendations and promoting for sustainability • Insight into COPD population at practice and local healthcare economy level to allow sharing best practice and evaluation of care provision to support clinical governance and support equity of care • Opportunity to upskill primary care doctors and nurses • Prescribing inline with national sustainability aspirations where clinically appropriate for patients • An environment to support the delivery of improved health outcomes for the COPD patient population • Potential reduction in COPD- related interventions, including hospital admissions • Increase engagement with the local respiratory network
GSK	<ul style="list-style-type: none"> • Helps GSK to live its value of being a patient focussed company. • Demonstrate partnership working • Expansion of the COPD patient population who are managed according to current clinical and best practice guidelines as a result of the programme • Potential increase in prescribing of on-formulary dry powder inhaler products within class if clinically appropriate for patients, aligned to the sustainability agenda – which may include GSK products.

GlaxoSmithKline (UK Ltd) and Hampshire and Isle of Wight Integrated Care System (NHS Hampshire, Southampton and Isle of Wight Clinical Commissioning Group) Executive Summary

	<ul style="list-style-type: none">• Increase in the appropriate use of medicines licensed for COPD aligned to local guidance, will likely increase the prescribing of GSK products as well as those of other pharmaceutical companies.• Better understanding of the challenges faced by the NHS in delivering high-quality patient services and care• Broadening of professional network
--	--